Onconetix, Inc. (ONCO)
Automate Your Wheel Strategy on ONCO
With Tiblio's Option Bot, you can configure your own wheel strategy including ONCO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ONCO
- Rev/Share 1.4322
- Book/Share 31.4074
- PB 0.0027
- Debt/Equity 0.2984
- CurrentRatio 0.0604
- ROIC -0.4629
- MktCap 3082910.0
- FreeCF/Share -5.9985
- PFCF -0.3935
- PE -0.0018
- Debt/Assets 0.1634
- DivYield 0
- ROE -1.2611
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May 20, 2025 indicating that the Company's failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the “10-Q”) is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”).
Read More
Onco-Innovations Uplists to Cboe Canada
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
TORONTO--(BUSINESS WIRE)---- $ONCO #Cboe--Cboe Canada is pleased to announce that Onco-Innovations Limited is available for trading under the ticker symbol ONCO.
Read More
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced that new clinical data of Proclarix® was presented on March 23, 2025 during the 2025 European Association of Urology (EAU) congress, which data further demonstrates the strong clinical performance of Proclarix® in a Danish cohort.
Read More
About Onconetix, Inc. (ONCO)
- IPO Date 2022-02-18
- Website https://onconetix.gcs-web.com
- Industry Biotechnology
- CEO Ms. Karina M. Fedasz
- Employees 12